LOX and myeloproliferative neoplasm: In preclinical studies, inhibition of lysyl oxidase has been shown to attenuate progression of myelofibrosis, a myeloproliferative neoplasm, and triple-negative breast cancer and thus is a promising novel therapy (172, 173, 174).